All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @mesa_trt on TikTok · 48s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @mesa_trt's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Are you injecting testosterone wrong?
  2. 0:02A lot of people ask that question to us
  3. 0:04each and every single day.
  4. 0:05They're like, hey, how do I inject it?
  5. 0:07Do I have to inject it into my backside?
  6. 0:08Do I have to do it into my arm?
  7. 0:10The simple and the most basic answer is
  8. 0:12you can inject it intramuscularly
  9. 0:14or you can inject it subcutaneously or into the skin.
  10. 0:18So the way that the testosterone breaks down in our body,
  11. 0:21the half-life is only a few days,
  12. 0:23regardless of whether it's in the muscle or not.
  13. 0:25In our office, we'll always tell our patients
  14. 0:28to inject two days a week.
  15. 0:30And so a lot of offices, they might say,
  16. 0:32hey, once a week or every other week.
  17. 0:34But two days a week, we find this optimum.
  18. 0:37For some people, if they really are wanting to be dialed in,
  19. 0:41we'll even say, hey, once a day,
  20. 0:43injecting daily microdosing is also a possibility
  21. 0:46for some of our patients as well.

@mesa_trt's testosterone injection advice, fact-checked

Mesa TRT

TikTok creator

76.6K viewsWatch on TikTok

Quick answer

Testosterone cypionate and enanthate are long-ester formulations with half-lives of approximately 8 and 4-5 days respectively, making injection frequency a legitimate clinical variable that affects peak-to-trough serum stability. Twice-weekly dosing is supported by pharmacokinetic logic and is common in clinical practice, but it is not universally mandated by evidence for all patients on all formulations. Both intramuscular and subcutaneous delivery routes have demonstrated clinical validity, with subcutaneous injection showing comparable bioavailability in peer-reviewed literature.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 4 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @mesa_trt's testosterone injection advice, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@mesa_trt's testosterone injection advice, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@mesa_trt's testosterone injection advice, fact-checked" from Mesa TRT. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Testosterone cypionate and enanthate are long-ester formulations with half-lives of approximately 8 and 4-5 days respectively, making injection frequency a legitimate clinical variable that affects peak-to-trough serum stability.

The reason this review is not generic is the source wording and the canonical claim label "trt are you injecting testosterone wrong it s a common questi." In this clip, the useful excerpt is: "Are you injecting testosterone wrong?" That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Subcutaneous injection is a legitimate delivery route backed by peer-reviewed data.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Testosterone cypionate and enanthate are long-ester formulations with half-lives of approximately 8 and 4-5 days respectively, making injection frequency a legitimate clinical variable that affects peak-to-trough serum stability.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Testosterone cypionate and enanthate are long-ester formulations with half-lives of approximately 8 and 4-5 days respectively, making injection frequency a legitimate clinical variable that affects peak-to-trough serum stability. Twice-weekly dosing is supported by pharmacokinetic logic and is common in clinical practice, but it is not universally mandated by evidence for all patients on all formulations. Both intramuscular and subcutaneous delivery routes have demonstrated clinical validity, with subcutaneous injection showing comparable bioavailability in peer-reviewed literature.
  • Testosterone cypionate has a half-life of approximately 8 days, not 'a few days.' This distinction directly affects how clinicians think about dosing intervals.
  • Subcutaneous injection is a legitimate delivery route backed by peer-reviewed data. Kaminetsky et al. (2011) confirmed comparable bioavailability and tolerability versus intramuscular injection.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Testosterone cypionate has a half-life of approximately 8 days, not 'a few days.' This distinction directly affects how clinicians think about dosing intervals.
  • Subcutaneous injection is a legitimate delivery route backed by peer-reviewed data. Kaminetsky et al. (2011) confirmed comparable bioavailability and tolerability versus intramuscular injection.
  • Twice-weekly dosing reduces peak-to-trough serum variability, which Spratt et al. (2017, JCEM) found to be a meaningful clinical benefit for hormonal steadiness.
  • No large randomized controlled trial has designated twice-weekly dosing as universally 'optimum.' Patient variability, ester type, and lab monitoring all influence what schedule is appropriate.
  • Daily microdosing has biological rationale but is not standard of care and is unsupported by large controlled trials. It requires significantly more patient adherence.
  • Every-other-week and weekly protocols are not automatically inferior. They remain appropriate for some patients when managed with proper lab monitoring, per Endocrine Society guidance.
  • Your dosing schedule should be determined by your provider based on your specific ester, serum labs, hematocrit, and symptom profile, not by a general social media recommendation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @mesa_trt actually say?

The creator from Mesa TRT walked through testosterone injection basics, covering intramuscular versus subcutaneous delivery, then made a specific scheduling claim: "two days a week, we find this optimum." They also mentioned that some patients are told to inject daily as a microdosing strategy. The video frames twice-weekly dosing as a clear upgrade over the once-weekly or every-other-week schedules many other clinics use.

That scheduling claim is the part worth scrutinizing. The IM vs. subcutaneous distinction is generally sound. But when a clinic says their dosing frequency is "optimum," that word is doing a lot of work and deserves pushback.

Does the science back this up?

Partly, yes. The rationale for splitting doses is real, but "optimum" is a stronger claim than the evidence supports for every patient. Testosterone cypionate has a half-life of roughly 8 days, and enanthate around 4-5 days. That is longer than the creator suggests when they say "a few days."

More frequent injections do reduce peak-to-trough variability, which matters for symptom stability and hematocrit management. A 2017 study by Spratt et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that more frequent, smaller doses produce steadier serum testosterone levels compared to less frequent large doses. A 2021 review by Handelsman in Endocrine Reviews also supports that injection frequency affects hormonal steadiness. However, no large randomized controlled trial has declared twice-weekly dosing categorically superior for all TRT patients. Daily microdosing has clinical rationale but even less formal trial data behind it.

What did they get wrong (or right)?

The half-life claim is the clearest factual error here. Testosterone cypionate has a half-life closer to 8 days, not "a few days." This matters because the half-life is exactly the pharmacokinetic reason clinicians argue about dosing schedules. Getting it wrong undermines the explanation, even if the practical recommendation ends up reasonable.

The IM versus subcutaneous framing is accurate. Research by Kaminetsky et al. (2011, Journal of Sexual Medicine) and subsequent clinical experience have confirmed that subcutaneous testosterone injection is a legitimate, well-tolerated delivery route that produces stable serum levels. Credit where it is due: the creator is not wrong to present both as valid options.

The framing of twice-weekly as "optimum" is an overclaim. It may be optimal for many patients, and the physiological logic is solid. But patients on longer ester formulations injecting every two weeks can also maintain acceptable levels if monitored properly. Calling one schedule universally optimum oversimplifies individualized care.

What should you actually know?

Injection frequency should be driven by your specific ester, your lab values, and how you feel, not a blanket protocol. Testosterone cypionate and enanthate are the two most common esters in the U.S., and their longer half-lives mean every-other-week dosing is not automatically wrong for everyone. It does, however, create wider hormonal swings that some patients notice as mood and energy fluctuations.

Subcutaneous injection into abdominal fat or the lateral thigh is supported by real clinical data and is genuinely easier for self-injection. If your current protocol uses IM only, asking your provider about subcutaneous is a reasonable conversation.

  • Twice-weekly dosing reduces hormonal peaks and troughs, which most endocrinologists consider a practical benefit.
  • Daily microdosing has biological rationale but is not standard of care and requires more patient burden.
  • Always confirm your injection schedule with the provider managing your labs, not a TikTok protocol.

Bottom line

This video gets the fundamentals directionally correct but overstates certainty. The half-life error is a real inaccuracy that a clinic operating at this scale should not be making publicly. The twice-weekly recommendation is reasonable clinical practice, but labeling it "optimum" without acknowledging patient variability or ester differences is the kind of confident overreach that sounds authoritative and is not fully earned by the data.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Mesa TRT · TikTok creator

76.6K views on this video

Are you injecting testosterone "wrong"? It's a common question, and we get it a lot here at MesaTRT. People wonder about injection sites—should it be in your backside, your arm? The simplest answer is

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about testosterone cypionate has a half-life of approximately 8 days, not?

Testosterone cypionate has a half-life of approximately 8 days, not 'a few days.' This distinction directly affects how clinicians think about dosing intervals.

What does the video say about subcutaneous injection?

Subcutaneous injection is a legitimate delivery route backed by peer-reviewed data. Kaminetsky et al. (2011) confirmed comparable bioavailability and tolerability versus intramuscular injection.

What does the video say about twice-weekly dosing reduces peak-to-trough serum variability,?

Twice-weekly dosing reduces peak-to-trough serum variability, which Spratt et al. (2017, JCEM) found to be a meaningful clinical benefit for hormonal steadiness.

What does the video say about no large randomized controlled trial has designated twice-weekly dosing as?

No large randomized controlled trial has designated twice-weekly dosing as universally 'optimum.' Patient variability, ester type, and lab monitoring all influence what schedule is appropriate.

What does the video say about daily microdosing has biological rationale?

Daily microdosing has biological rationale but is not standard of care and is unsupported by large controlled trials. It requires significantly more patient adherence.

What does the video say about every-other-week?

Every-other-week and weekly protocols are not automatically inferior. They remain appropriate for some patients when managed with proper lab monitoring, per Endocrine Society guidance.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Mesa TRT, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.